LSE:AZNPharmaceuticals
AstraZeneca (LSE:AZN) Stock Looks Cheap On Cash Flow While Broader Checks Stay Mixed
AstraZeneca stock has delivered a 73.3% return over the past five years, yet current valuation checks suggest the market price may still sit below an estimate of intrinsic value based on a Discounted Cash Flow (DCF) model and earnings multiples. With fresh headlines around cancer drug developments and mixed analyst views, investors are weighing whether that apparent discount fairly reflects the company’s growth prospects and risks.
Over five years, AstraZeneca shares are up 73.3%, which...